PLEASANTON, Calif., Nov. 20, 2023 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) begins taking orders for the Evie Ring, the smart ring designed specifically for women, today at 12 pm EST. An innovative and comfortable form factor, a focus on helping women track and analyze their health and fitness, and an emphasis on big-picture data interpretation rather than individual activity scores set Evie apart from other wearables, providing a valuable new tool for women seeking to take control of their health.
Built from the ground up using research that uncovers the differences between men's and women's biomarkers as well as interviews with more than 1,000 women about their health and wellness needs, Evie monitors key health and wellness metrics. Biometric sensors track sleep stages and duration, resting heart rate, heart rate variability, blood oxygen saturation (SpO2), respiration rate, skin temperature trends, steps, active minutes, and calorie burn; while users log information ranging from mood and menstrual symptoms, which enables the estimation of periods and ovulation, to illness, stress and alcohol consumption.
These core functions are integrated into a smart ring and companion app that break new ground in the wearable space. Unique features include:
Evie also includes a Spot Check feature enabling users to measure their heart rate and blood oxygen levels at any time, day or night. This is a useful function that can help users who aren't feeling well determine whether to consult with their healthcare providers.
The ring has 4+ days of battery life, and recharges in just 60 minutes. Additionally, Evie comes with a portable charging case that holds 10+ ring charges so users can charge their ring from anywhere and at any time.
The Evie Ring is available exclusively through www.eviering.com in gold, rose gold, and silver finishes and in sizes 5-12 with a complimentary sizing kit for those who don't know their ring size. It costs $269 with no subscription fees. Ring orders will ship January 2024.
About Movano Health
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health is developing a suite of purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. Featuring modern form factors, Movano Health's devices capture a comprehensive picture of a person's vital health information and uniquely translate the data into personalized and intelligent insights that empower consumers to live healthier and more balanced lives. Movano Health's end-to-end solutions will soon enable consumers and their healthcare professionals to utilize daily medical-grade data as a tool to proactively monitor and manage health outcomes. For more information on Movano Health, visit https://movanohealth.com/.
Forward Looking Statements
This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding anticipated FDA clearance for the Evie Ring; expected future operating results; product development and features, product releases, clinical trial, and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Last Trade: | US$0.94 |
Daily Change: | -2.17 -69.77 |
Daily Volume: | 21,003 |
Market Cap: | US$6.200M |
March 10, 2025 January 08, 2025 January 02, 2025 December 02, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load